Secretory effect of @entity18573 ( @entity18573 ) on the short circuited mucosa of the XXXX ileum in vitro.

@entity1 @entity2983 @entity294 @entity1372 @entity1483 @entity2918 @entity18573 @entity841 @entity2865 @entity35 @entity3352 @entity37065 @entity3378
@entity18573 ( @entity37065 ) is one of the newly developed substitutes of @entity3378 consisting of two molecules of @entity2983 . @entity18573 caused @entity294 in some @entity1 , apparently caused by an antiabsorptive secretagogue action of this compound. The mechanism of this was studied in the short circuited isolated mucosa of the @entity35 ileum. Mucosal addition of ADS increased the @entity841 ( @entity841 ) and short circuit current (Isc) at a concentration of 1.3.10(-4) mol/l (4 mg/dl) with maximal effects at 1.3.10(-3) mol/l (40 mg/dl). Epithelial resistance was only slightly decreased at the higher concentrations of 40 and 100 mg/dl. Serosal ADS had no effect on electrical parameters. The increase of Isc was associated with a change of net @entity2865 absorption into net secretion. Net @entity1372 absorption was only slightly and not significantly decreased. The changes were reversible after rinsing away the ADS. Treatment of the mucosa with @entity1483 inhibited the ADS induced increase of Isc, suggesting transcellular pathway for the ADS stimulated secretion. Biosynthesis of @entity2918 is not involved in the mechanism of this secretion, as treatment with @entity3352 did not alter the effect of ADS on Isc. Results suggest that ADS can be considered as a secretagogue, which stimulates intestinal secretion via a transcellular pathway. Because of the bacterial cleavage of the double molecule into two molecules of the non-secretagogue @entity2983 in the colon, however, @entity294 may develop only in @entity1 with a decreased absorptive capacity of the colon, or insufficient cleavage of ADS.
